The possibility of that Alzheimer disease (AD)-modifying treatments such as amyloid beta-protein (Abeta) immunotherapies being available raises an urgent need for biological markers that will facilitate early and accurate diagnosis. This concept is now widely accepted,because without doubts that such treatments should be initiated during the early stages of the disease. In this review, we discusses the recent progress in identification of biological markers by placing a particular focus on Abeta and tau.